Board of Directors
Kenneth Widder, MD
Ken is an M.D. with over 30 years of experience working with biomedical companies. He has founded six companies and was Chairman/CEO of six of these. He was a General Partner at Latterell Venture Partners (LVP Life Science Ventures) and before that, was a General Partner at Windamere Venture Partners.
His last company, which he co-founded and was CEO and Chairman, Sytera Inc., merged with Sirion Therapeutics, an ophthalmology specialty pharmaceutical company. Prior to Sytera, Ken was a founder and CEO of NovaCardia, a company acquired by Merck. Prior to NovaCardia, Ken was a founder, Chairman, and CEO of Santarus (NASDAQ:SNTS), which was acquired by Salix. Additionally he was Chairman and CEO of Converge Medical, a medical device company developing a sutureless anastamosis system for vein grafts in coronary artery by-pass surgery.
Ken started his career as a founder, Chairman and CEO of Molecular Biosystems (NYSEMB), where he was responsible for the development and approval of Albunex and Optison, the first two ultrasound contrast agents to be approved in the U.S. He currently sits on the boards of Evoke Pharma, Quidel, and OrphoMed.
Ken holds an M.D. from Northwestern University and trained in pathology at Duke University. He is an inventor on over 30 patents and patent applications and has authored or co-authored over 25 publications.
Michael Martin, PhD
Global Head of Takeda Ventures, Inc.
Dr. Michael Martin is the global head of Takeda Ventures, Inc. (TVI) and he is based in San Diego, CA. His professional background includes venture capital, pharma business development and broad R&D experiences with an integral role in the discovery and development of 17 innovative investigational drugs and 2 commercial products. Prior to joining TVI, Dr. Martin was most recently a member of Global Licensing and Business Development at Takeda, heading efforts for sourcing and transacting technologies and early stage pipeline programs. Dr. Martin has held executive and scientific roles with Intellikine (acquired by Takeda), TargeGen (acquired by Sanofi-Aventis), Arena Pharmaceuticals and Monsanto Corporation.
Dr. Martin is currently a director at ArmaGen, Avidity Biosciences, BioMotiv, Bioniz, Cortexyme, FutuRx, OrphoMed, Univercells and an advisor to Arix Biosciences, Atlas Ventures and UK Dementia Discovery Fund.
Dr. Martin earned his doctorate in Medicinal Chemistry from the University of Illinois and holds a M.S. degree in analytical chemistry and B.S. degrees in Chemistry and Mathematics.
Managing Partner, Pappas Capital
Art has over 30 years’ experience as a pharmaceutical executive and life science venture capital investor. He founded Pappas Capital in 1994 and since then has raised over $520 million. Prior to Pappas Capital, Art held senior leadership positions at Glaxo Holdings, Abbott International, Merrell Dow Pharmaceuticals and the Dow Chemical Company.
Art is currently a director for Aura Biosciences and OrphoMed. He also serves on several non-profit boards including the North Carolina Biotechnology Center and The Wistar Institute. He is a decorated Vietnam veteran, having served in the US Army 101st Airborne Division. Art received a BS in Biology from Ohio State University and an MBA in Finance from Xavier University.
Frank Torti, MD
Dr. Frank Torti joined NEA in 2007 and is a Partner focused on investments in biopharmaceuticals, medical devices, and healthcare services. He has been actively involved in the firm’s investments in healthcare, includingAnnexon Biosciences, Alimera Sciences, Cadence Pharmaceuticals (acquired by Mallinckrodt plc), CITIC Pharmaceuticals (acquired by Shanghai Pharmaceuticals), Dermira, Eargo, GST Clinics, Galera Therapeutics, Neotract, Novast Pharmaceuticals, Orphomed, Peplin (acquired by LEO Pharma), Rigel, Solta Medical (acquired by Valeant), and Tarveda Therapeutics.
Prior to joining NEA, Dr. Torti worked for the Duke University Center for Clinical & Genetic Economics, where he was involved in clinical trials research and economic evaluations of multinational clinical trials. Dr. Torti received his medical degree from the University of North Carolina School of Medicine, his MBA with distinction from Harvard Business School, and his BA with highest honors from the University of North Carolina, where he was a Morehead Scholar.
Nikhilesh Singh, PhD
President and Chief Executive Officer
Nikhilesh Singh, Ph.D., Co-founder and Chief Executive Officer of OrphoMed, has more than 25 years of leadership experience in the development and commercialization of pharmaceutical products, including OTC and prescription drugs. He is the primary inventor on several U.S. and international patents that cover a products ranging from OTC (Vicks® Formula 44), prescription (Intermezzo®) and new chemical entities, including OrphoMed’s novel dimer therapeutics. Dr. Singh founded OrphoMed in 2014 to develop drugs based on a proprietary dimer technology platform. Previously, Dr. Singh founded Transcept Pharmaceuticals to develop, launch, and commercialize Intermezzo®, a proprietary, novel sublingual tablet for the treatment of insomnia.
Dr. Singh is a Fellow of the American College of Clinical Pharmacology and earned a Ph.D. in Pharmaceutical Sciences from the University of Alberta, Canada.